These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2669997)

  • 1. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.
    Gilbert HS; Praloran V; Stanley ER
    Blood; 1989 Sep; 74(4):1231-4. PubMed ID: 2669997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
    Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
    Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
    Bartl R; Frisch B; Wilmanns W
    Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum procollagen III peptide in chronic myeloproliferative disorders.
    Hasselbalch H; Junker P; Lisse I; Bentsen KD
    Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelosclerosis in agnogenic myeloid metaplasia.
    Feldman F
    Semin Roentgenol; 1974 Jul; 9(3):195-207. PubMed ID: 4601848
    [No Abstract]   [Full Text] [Related]  

  • 14. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 15. Myelopoietic effect of bone marrow fibroblasts cultured from patients with myelofibrosis.
    Wang JC
    Am J Hematol; 1988 Apr; 27(4):235-41. PubMed ID: 3258473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.